trial

The Effects of Atomoxetine on Cognition and Brain Function Based on Catechol-O-methyltransferase(COMT) Genotype

NCTId NCT00548327
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Terminated
Enrollment 11 (actual)
Sponsored by National Institute of Mental Health (NIMH)
Primary completion 2011-11
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Terminated
Enrollment
11 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Quadruple
Start
2007-10
Primary completion
2011-11
Eligibility
ALL · 18 Years · 45 Years

Interventions & indications

Drugs
atomoxetineFunctional magnetic resonance imagingneuropsychological testing

Sponsors

National Institute of Mental Health (NIMH)Lead Sponsor

Investigators

1
Jose A Apud, M.D.Principal Investigator

Sites

1 total
Bethesda, United States

Linked catalysts

1
The Effects of Atomoxetine on Cognition and Brain Function Based on Catechol-O-m — primary completion2011-11

Facts & assertions

4 sourced
Enrollment
11
Phase
PHASE2
Primary Completion Date
2011-11
Status
TERMINATED
relationships
The graph out of here
drug
atomoxetine
drug
Functional magnetic resonance imaging
drug
neuropsychological testing
drug
lead_sponsor
National Institute of Mental Health (NIMH)
company
indication
Memory Disorders
indication
Memory Disorders
indication
Schizophrenia
indication
investigator
Jose A Apud, M.D.
person